Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population

Cancer

Volumn 112, Issue 4, 2008, Pages 789-799

  Dobie, Sharon A ^a   Warren, Joan L ^b   Matthews, Barbara ^a   Schwartz, David ^c   Baldwin, Laura Mae ^a   Billingsley, Kevin ^d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Adjuvant therapy; Cancer mortality; Chemotherapy; Radiation therapy; Rectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECTUM CANCER; SUPPORT GROUP;

AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; MALE; MEDICARE; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 39049148628     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23244     Document Type: Article

References (46)

1. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med. 1985;312:1465-1472.
2. Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988;80:21-29.
3. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444-1450.
4. Douglass HO Jr, Moertel CG, Mayer RJ, et al. Survival after postoperative combination treatment of rectal cancer. N Engl J Med. 1986;315:1294-1295.
5. Tepper JE, O'Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control - final report of intergroup 0114. J Clin Oncol. 2002;20:1744-1750.
6. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. J Clin Oncol. 1992;10:549-557.
7. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994;331:502-507.
8. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324:709-715.
9. Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM. Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol. 2006;101:2308-2318.
10. Dharma-Wardene MW, de Gara C, Au HJ, Hanson J, Hatcher J. Ageism in rectal carcinoma? Treatment and outcome variations. Int J Gastrointest Cancer. 2002;32:129-138.
11. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002;20:1192-1202.
12. Neugut AI, Fleischauer AT, Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol. 2002;20:2643-2650.
13. Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results - Medicare. J Clin Oncol. 2001;19:3712-3718.
14. Miller RC, Martenson JA, Sargent DJ, Kahn MJ, Krook JE. Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. Int J Radiat Oncol Biol Phys. 1998;41:593-598.
15. Kollmorgen CF, Meagher AP, Wolff BG, Pemberton JH, Martenson JA, Illstrup DM. The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg. 1994;220:676-682.
16. Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, Barlow W. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst. 2006;98:610-619.
17. Greene FL, Page DL, Fleming ID, et al., eds. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2002.
18. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002;40(8 suppl):IV-49-54.
19. Du X, Freeman JL, Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked Medicare and SEER data. Surveillance, Epidemiology and End Results. J Clin Epidemiol. 1999;52:463-470.
20. Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA. Construct validity of Medicare chemotherapy claims: the case of 5FU. Med Care. 2002;40:201-211.
21. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 suppl):IV-55-61.
22. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16:295-300.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
24. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-1079; discussion, 1081-1090.
25. Morrill R, Cromartie J, Hart LG. Metropolitan, urban, and rural commuting areas: toward a better depiction of the US settlement system. Urban Geogr. 1999;20:727-748.
26. WWAMI Rural Health Research Center. Rural-urban commuting area codes (version 2.0). Available at: http.//depts.washington.edu/uwruca/ Accessed February 20, 2007.
27. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690-1691.
28. Baxter NN, Rothenberger DA, Morris AM, Bullard KM. Adjuvant radiation for rectal cancer: do we measure up to the standard of care? An epidemiologic analysis of trends over 25 years in the United States. Dis Colon Rectum. 2005;48:9-15.
29. Minsky BD, Cohen AM, Kemeny N, et al. Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J Clin Oncol. 1992;10:1218-1224.
30. Osti MF, Valeriani M, Masoni L, Tombolini V, Enrici RM. Neoadjuvant chemoradiation for locally advanced carcinoma of the rectum. Tumori. 2004;-309.
31. Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg. 1990;211:187-195.
32. Ahmad NR, Marks G, Mohiuddin M. High-dose preoperative radiation for cancer of the rectum: impact of radiation dose on patterns of failure and survival. Int J Radiat Oncol Biol Phys. 1993;27:773-778.
33. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-1740.
34. Valero G, Lujan JA, Hernandez Q, et al. Neoadjuvant radiation and chemotherapy in rectal cancer does not increase post-operative complications. Int J Colorectal Dis. 2003;18:495-499.
35. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638-646.
36. Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg. 1998;133:894-899.
37. Enker WE, Thaler HT, Cranor ML, Polyak T. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg. 1995;181:335-346.
38. Bulow S, Christensen IJ, Harling H, Kronborg O, Fenger C, Nielsen HJ. Recurrence and survival after mesorectal excision for rectal cancer. Br J Surg. 2003;90:974-980.
39. Habr-Gama A, Perez RO, Kiss DR, et al. Preoperative chemoradiation therapy for low rectal cancer. Impact on downstaging and sphincter-saving operations. Hepatogastroenterology. 2004;51:1703-1707.
40. Tepper JE, O'Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol. 2001;19:157-163.
41. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004;22:1785-1796.
42. Greene FL, Stewart AK, Norton HJ. New tumor-node-metastasis staging strategy for node-positive (stage III) rectal cancer: an analysis. J Clin Oncol. 2004;22:1778-1784.
43. Jeong SY, Chessin DB, Schrag D, Riedel E, Wong WD, Guillem JG. Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2005;97:1705-1706; author reply 1706-1707.
44. Comment on: J Natl Cancer Inst. 2004;96:1408-1409
45. and J Natl Cancer Inst. 2004;96:1420-1425.
46. Guillem JG, Chessin DB, Cohen AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241:829-836; discussion 836-828.